GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » EBITDA

Cosmos Health (Cosmos Health) EBITDA : $-12.98 Mil (TTM As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health EBITDA?

Cosmos Health's EBITDA for the three months ended in Sep. 2023 was $-3.02 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.98 Mil.

During the past 3 years, the average EBITDA Growth Rate was -108.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Cosmos Health was 55.40% per year. The lowest was -302.90% per year. And the median was -28.65% per year.

Cosmos Health's EBITDA per Share for the three months ended in Sep. 2023 was $-0.24. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.18.

During the past 12 months, the average EBITDA per Share Growth Rate of Cosmos Health was -823.90% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -35.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Cosmos Health was 57.90% per year. The lowest was -274.30% per year. And the median was -23.30% per year.


Cosmos Health EBITDA Historical Data

The historical data trend for Cosmos Health's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmos Health EBITDA Chart

Cosmos Health Annual Data
Trend Jul13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.19 -0.99 4.39 -3.82 -8.90

Cosmos Health Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -9.19 -0.25 -0.52 -3.02

Competitive Comparison of Cosmos Health's EBITDA

For the Medical Distribution subindustry, Cosmos Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmos Health's EV-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cosmos Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cosmos Health's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cosmos Health's EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Cosmos Health's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2022, Cosmos Health's EBITDA was $-8.90 Mil.

Cosmos Health's EBITDA for the quarter that ended in Sep. 2023 is calculated as

Cosmos Health's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2023, Cosmos Health's EBITDA was $-3.02 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Cosmos Health  (NAS:COSM) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Cosmos Health EBITDA Related Terms

Thank you for viewing the detailed overview of Cosmos Health's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmos Health (Cosmos Health) Business Description

Traded in Other Exchanges
Address
141 West Jackson Boulevard, Suite 4236, Chicago, IL, USA, 60604
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers.
Executives
Grigorios Siokas 10 percent owner 5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Suhel Bhutawala director 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis officer: Chief Operating Officer 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler director 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis director 11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades officer: Chief Operating Officer KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Georgios Terzis officer: Chief Financial Officer 2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Peter Goldstein director 151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas director 9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos director, 10 percent owner, officer: CEO 141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis director, officer: Secretary PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos director, 10 percent owner, officer: CEO 200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis director, 10 percent owner, officer: CFO TERTSETI 23 STREET, KESARIANI J3 16122

Cosmos Health (Cosmos Health) Headlines

From GuruFocus

Cosmos Health Starts Stock Buyback Program

By ACCESSWIRE 09-13-2023